Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Uric acid

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    126 result(s) found for: Uric acid. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2021-003176-14 Sponsor Protocol Number: LPS15679 Start Date*: 2021-06-29
    Sponsor Name:Sanofi-Aventis Groupe
    Full Title: An Open-label, Single-arm, Multi-center Study to Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients with Non-Hodgkin...
    Medical condition: Hyperuricemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020907 Hyperuricemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-003989-24 Sponsor Protocol Number: L_9436 Start Date*: 2014-12-19
    Sponsor Name:Sanofi
    Full Title: Program of Rasburicase in the Treatment of Hyperuricemia in Children and Adolescent Patients With or at Risk of Tumor Lysis Syndrome
    Medical condition: Hyperuricemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10020907 Hyperuricemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-002315-41 Sponsor Protocol Number: RDEA806-501 Start Date*: 2008-08-13
    Sponsor Name:Ardea Biosciences, Inc.
    Full Title: Randomized, Double-Blind, Multicenter, Placebo-Controlled, Dose Ranging, Efficacy and Safety Study of RDEA806 in Hyperuricemic Subjects with Symptomatic Gout
    Medical condition: Gout
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018627 Gout LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001786-26 Sponsor Protocol Number: 3004 Start Date*: 2014-07-02
    Sponsor Name:Steno Diabetes Center
    Full Title: A randomised, doublet blinded, placebo controlled cross-over study of Allopurinols effect to prevent loss of kidney function in type 1 diabetes
    Medical condition: Type 1 diabetes and microalbuminuria.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004848 10037827 Raised serum uric acid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-001858-25 Sponsor Protocol Number: MEIN/11/FEB-GOU/001 Start Date*: 2013-01-28
    Sponsor Name:MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.
    Full Title: A multicentre, randomised, double-blind, parallel group study on the therapeutic efficacy and safety of Febuxostat (taken once daily) and the therapeutic efficacy and safety of Allopurinol on serum...
    Medical condition: hyperuricemia and gout
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10018627 Gout PT
    14.1 10027433 - Metabolism and nutrition disorders 10020907 Hyperuricemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) IT (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-004042-42 Sponsor Protocol Number: DEER Start Date*: 2014-06-19
    Sponsor Name:King’s College London [...]
    1. King’s College London
    2. Guy's and St Thomas NHS Foundation Trust
    Full Title: A study to investigate the potential renoprotective role of sodium-glucose transporter-2 (SGLT-2) antagonist Dapagliflozin in Type 2 diabetic patients with diabetic nephropathy
    Medical condition: Diabetic Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-001809-16 Sponsor Protocol Number: Unidone-01 Start Date*: 2016-09-14
    Sponsor Name:Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
    Full Title: Efficacy and safety of chlorthalidone 25 mg in hypertensive patients.
    Medical condition: BP lowering effect of chlorthalidone 25 mg in essential hypertensive patients.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10045866 Unspecified essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2017-001191-30 Sponsor Protocol Number: RDEA594-401 Start Date*: 2017-09-27
    Sponsor Name:Ironwood Pharmaceuticals, Inc.
    Full Title: A Phase 4, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lesinurad 200 mg in Combination With a Xanthine Oxidase Inhibitor (XOI), Compared W...
    Medical condition: Gout and moderate renal impairment
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10018627 Gout PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001341-27 Sponsor Protocol Number: Empire-2017 Start Date*: 2017-05-29
    Sponsor Name:Morten Schou
    Full Title: Empagliflozin in heart failure patients with reduced ejection fraction: A randomized clinical trial (Empire HF)
    Medical condition: Heart failure with reduced ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10078289 Heart failure with reduced ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-000127-42 Sponsor Protocol Number: NRSily1 Start Date*: 2005-03-03
    Sponsor Name:Medical University of Vienna
    Full Title: Non Responder- STUDY: MULTICENTER STUDY TO EVALUATE THE EFFICACY OF SILYMARIN IN ADDITION TO COMBINATION-THERAPY WITH PEGYLATED INTERFERON ALFA 2A (PEG-IFN ALFA 2A) AND RIBAVIRIN IN PATIENTS WI...
    Medical condition: HCV-patients, who have not responded to a previous therapy with INF or PEG-INF +/- Ribavirin.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002349-12 Sponsor Protocol Number: RALBAT Start Date*: 2013-08-17
    Sponsor Name:Unit of Infectious Diseases, Department of Medical Scieces, University of Torino c/o ASLTO2, Amedeo di Savoia Hospital
    Full Title: “Switching HIV-positive Women With Undetectable Viremia on Tenofovir/Emtricitabine plus Boosted Atazanavir to RALtegravir (400 mg twice-daily) plus Boosted ATazanavir (300/100 mg once-daily): A Pil...
    Medical condition: HIV infection, osteopenia
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004152-10 Sponsor Protocol Number: EMPATHY Start Date*: 2020-01-30
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: Evaluating the Short-Term Renal and Systemic Effects of SGLT2 Inhibition in Non-Diabetic Patients at Risk of Accelerated GFR Decline Because of Glomerular Hyperfiltration: a sequential OFF-ON-OFF S...
    Medical condition: Obesity Renal chronic disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    21.1 100000004857 10009119 Chronic renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002758-25 Sponsor Protocol Number: NL2020-01 Start Date*: 2024-01-02
    Sponsor Name:Reade Jan van Breemen Instituut
    Full Title: Treatment of severe gout patients with rasburicase
    Medical condition: Tophaceous gout
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003481-14 Sponsor Protocol Number: 3004 Start Date*: 2014-03-07
    Sponsor Name:National Institute of Diabetes and Digestive and Kidney Diseases
    Full Title: Study of allopurinol to prevent GFR loss in type 1 diabetes
    Medical condition: Type 1 diabetes, microalbuminuria or macroalbuminuria and mildly impaired kidney function.
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004848 10037827 Raised serum uric acid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-006994-10 Sponsor Protocol Number: SEQ-ALO-2007-01 Start Date*: 2009-02-04
    Sponsor Name:Fundación Investigación Biomédica Hospital Príncipe de Asturias
    Full Title: Evaluación de la utilidad del alopurinol en la prevención de la morbimortalidad cardiovascular de los pacientes con enfermedad renal crónica (ERC) e hiperuricemia EVALUATION OF THE USE OF ALLOPURI...
    Medical condition: Enfermedad renal crónica (ERC) e hiperuricemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020907 Hyperuricemia LLT
    9.1 10009119 Chronic renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-000757-21 Sponsor Protocol Number: P04823 Start Date*: 2006-08-15
    Sponsor Name:AESCA Pharma GmbH
    Full Title: Study to evaluate Response Rates in CHC Patients genotype 1 with Insulin Resistance and to assess prolonged Treatment Duration in late virological Responders
    Medical condition: chronic hepatitis C, genotype 1
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-005049-48 Sponsor Protocol Number: EFP01 Start Date*: 2008-11-20
    Sponsor Name:AZIENDA OSPEDALIERA FONDAZIONE MACCHI (A.O. DI RILIEVO NAZIONALE)
    Full Title: Coadministration of ezetimibe with fenofibrate versus pravastin monotherapy for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a randomized, prospective, ...
    Medical condition: HIV-infected patients with dislypidemia treated with PIs
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003768-55 Sponsor Protocol Number: RDEA594-304 Start Date*: 2012-05-14
    Sponsor Name:Ardea Biosciences, Inc.
    Full Title: A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Febuxostat Compared to Febuxostat Alone at Lowering S...
    Medical condition: Tophaceous Gout
    Disease: Version SOC Term Classification Code Term Level
    17.0 10027433 - Metabolism and nutrition disorders 10018627 Gout PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-004079-11 Sponsor Protocol Number: D5495C00002 Start Date*: 2019-06-28
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2b, Multicentre, Randomised, Double-blind, Placebo-controlled Study of Verinurad and Allopurinol in Patients with Chronic Kidney Disease and Hyperuricaemia
    Medical condition: Chronic kidney disease and hyperuricaemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) CZ (Completed) ES (Ongoing) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2021-000580-78 Sponsor Protocol Number: EMPAtia Start Date*: 2022-02-02
    Sponsor Name:The Children’s Memorial Health Institute
    Full Title: "The assessment of effectiveness and safeness of utilizing empagliflozin in the treatment of neutropenia of patients suffering from glycogenolysis type Ib"
    Medical condition: neutropenia and / or abnormal neutrophil function in glycogenosis I b
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 01:19:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA